News | ACC | March 21, 2018

ACC 2018 Late-Breaking Trials

Latest clinical data in cardiology will be presented at the 2018 American College of Cardiology meeting

ACC 2018 Late-Breaking Trials Announced

Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presented at ACC18, March 10-12 in Orlando, Fla. The studies are linked to articles specific to the trial presentations.

Preview some of the hot topics at at ACC 2018 with the editor's of the ACC journals in the article "What Trends are Ahead in Cardiovascular Medicine in 2018?"
 

 

Joint American College of Cardiology/Journal of American College of Cardiology Late-Breaking Clinical Trials
Saturday, March 10

Featured Clinical Research I
Saturday, March 10

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Sunday, March 11

Late-Breaking Clinical Trials
Sunday, March 11

Featured Interventional Clinical Research II
Sunday, March 11

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Monday, March 12

Late-Breaking Clinical Trials: Interventional Cardiology
Monday, March 12

Featured Interventional Clinical Research III
Monday, March 12

Other Featured Research:

CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials

Aspirin Lowers Risk of Death for Patients with Diabetes, Heart Failure

ECG on Smartwatch Accurately Detects AFib

Getting Flu Vaccine Cuts Risk of Death by Half in People with Heart Failure

Breastfeeding May Have Long-Term Heart Health Benefits for Some Moms

Marked Increase in Cardiovascular Risk Factors in Women After Preeclampsia

 

ACC.18 Video Interviews:

VIDEO: Editor's Choice of Most Innovative New Cardiac Technology at ACC 2018

VIDEO: Gender Differences in Diagnosing Heart Disease in Women — interview with Doreen DeFaria Yeh, M.D.

VIDEO: TAVR for Degenerated Surgical Valves — Valve-in-Valve TAVR Procedures — interview with Sammy Elmariah, M.D.

VIDEO: iFR Found More Cost Effective Over Standard FFR — interview with  Manesh Patel, M.D.

VIDEO: Addressing Adult Congenital Heart Referrals — discussion with Ami Bhatt, M.D.

VIDEO: How to Avoid Acute Kidney Injury in the Cath Lab —  discussion with Hitinder Gurm, M.D.

VIDEO: Therapies for Advanced Heart Failure — interview with David Lanfear M.D.

VIDEO: Detection of Vulnerable Plaque and Pre-emptive Stenting — discussion with Ron Waksman, M.D.

VIDEO: Strategies to Avoid Acute Kidney Injury Caused by Cath Lab Contrast — interview with Roxana Mehran, M.D.

 

 

 

 

Vendor Product News at ACC.18:

Siemens Healthineers Launches Next Generation of syngo Dynamics at ACC 2018

Infraredx Highlights Value of IVUS + NIRS for Detecting Lipid Core Plaque at ACC.18

CorFlow Presents New Insights Into Coronary Microcirculation at ACC

Siemens Healthineers Introduces Portable Cardiovascular-Dedicated Ultrasound at ACC.18

 

 

RELATED CONTENT

ACC 2017 Late-Breaking Trials

AHA 2017 Late-breaking Trials

Late-breaking Trial Presentations at ESC 2017

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

Late-Breaking Clinical Trial Presentations at SCAI 2017

TCT 2017 Late-breaking Clinical Trial Presentations

VIVA 2017 Late-breaking Clinical Trial Presentations

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | May 18, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announce
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle